HIF-PHIs for the Treatment of Anemia in CKD: Ready or Not?

Prof Daniel Coyne from Wash U St Louis, presents a scintillating and deep dive into the HIF-PHI data so far. Trawling into not just the published literature, but the FDA submissions, he discusses many important aspects of HIF-PHIs including:
Efficacy (including differences between agents, effect on iron uptake, role during inflammation)
and Safety in particular discussing the many facets one has to consider in the trial interpretation.
Are these drugs safer or more dangerous than existing ESAs?

[@shubharthidr]

Great TALK!!!